51 Result(s)

Article

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

Most randomized clinical trials evaluating second generation tyrosine kinase inhibitors (TKI) for the first-line treatment of Chronic Myeloid Leukemia used as comparator the ‘standard’ dose of 400 mg imatinib ...

Verena S. Hoffmann, Joerg Hasford… in Journal of Cancer Research and Clinical On… (2017)

Article

A linear regression model can estimate hip fracture incidence

Juan F. Blanco, Jorge Cortés, Agustin Diaz-Alvarez… in Archives of Osteoporosis (2011)

Article

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutive...

Michael S. Mathisen, Susan O’Brien… in Current Hematologic Malignancy Reports (2011)

Article

Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable progno...

Deborah A. Thomas, Susan O’Brien, Stefan Faderl… in Current Hematologic Malignancy Reports (2011)

Article

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients.

Gloria N. Mattiuzzi, Jorge Cortes, Gladys Alvarado… in Supportive Care in Cancer (2011)

Article

New model to explain the EQ-5D VAS in patients who have undergone spinal fusion

In the health sector, the EQ-5D has been widely used to evaluate health-related quality of life, mainly due to its simplicity, robustness and plasticity in calculating years of life adjusted for quality.

Jorge Cortés, Juan F. Blanco, David Pescador, Nuria Asensio… in Quality of Life Research (2010)

Article

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr-Abl kinase, imatinib leads t...

Meetu Agrawal, Ravin J. Garg, Hagop Kantarjian, Jorge Cortes in Current Oncology Reports (2010)

Article

Tyrosine Kinase Inhibitors: The First Decade

The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting this leukemogenic prot...

Meetu Agrawal, Ravin J. Garg, Jorge Cortes… in Current Hematologic Malignancy Reports (2010)

Article

Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation

Cytogenetic abnormalities in patients with essential thrombocythemia (ET) are infrequent. Their role in survival of patients and disease transformation is not extensively studied. We describe cytogenetic abnor...

Matjaz Sever, Hagop Kantarjian, Sherry Pierce… in International Journal of Hematology (2009)

Article

Imatinib and beyond—exploring the full potential of targeted therapy for CML

Imatinib is the standard frontline therapy for patients with chronic myeloid leukemia (CML); however, a substantial number require alternative therapy owing to imatinib intolerance or imatinib resistance. Stud...

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes in Nature Reviews Clinical Oncology (2009)

Article

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?

Imatinib mesylate, 400 mg/d, is considered standard therapy for managing patients with chronic myeloid leukemia (CML) in chronic phase, yielding high rates of cytogenetic responses that translate into favorabl...

Alfonso Quintás-Cardama, Jorge Cortes in Current Oncology Reports (2009)

Article

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to mye...

Roberto H. Nussenzveig, Jorge Cortes, Matjaz Sever… in International Journal of Hematology (2009)

Article

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia will achieve complete remission (CR). However, approximately 30% of these patients will relapse, including a small propo...

Arturo Vega-Ruiz, Stefan Faderl, Zeev Estrov… in International Journal of Hematology (2009)

Article

Treatment selection after imatinib resistance in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a const...

Elias Jabbour, Jorge Cortes, Hagop Kantarjian in Targeted Oncology (2009)

Article

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

A phase I study was performed to determine the safety and pharmacokinetics of XK469R in patients with refractory acute leukemia. The study aimed to determine the maximum tolerated dose (MTD) and dose limiting ...

Wendy Stock, Samir D. Undevia, Carol Bivins, Farhad Ravandi… in Investigational New Drugs (2008)